Cindy Atwell
Chief Development and Business Officer
Cindy Atwell is the Chief Development and Business Officer at Precision BioSciences, overseeing development functions including regulatory, translational, clinical, program leadership and management in addition to business development and alliance management. Cindy joined Precision BioSciences in 2019 and has served as its Chief Business Officer since 2022. She has over twenty years of multi-disciplinary experience in the biopharma industry including various roles at Halozyme, AbbVie, Amylin, Impax, and start-up biotech companies. Over the course of her career, Cindy has led or participated in the negotiation of a number of transactions, totaling >$10Bn in value. This includes the Novartis-Precision sickle cell gene editing strategic collaboration. Cindy holds a BS in biochemistry and molecular biology from the Pennsylvania State University and an MBA from the University of California, San Diego’s Rady School of Management.